IN2014MU00205A - - Google Patents

Download PDF

Info

Publication number
IN2014MU00205A
IN2014MU00205A IN205MU2014A IN2014MU00205A IN 2014MU00205 A IN2014MU00205 A IN 2014MU00205A IN 205MU2014 A IN205MU2014 A IN 205MU2014A IN 2014MU00205 A IN2014MU00205 A IN 2014MU00205A
Authority
IN
India
Prior art keywords
relates
mesalamine
suppositories
compositions
pharmaceutical
Prior art date
Application number
Other languages
English (en)
Inventor
Nilendusen
Sandhya Rajendra Shenoy
Imran Shakoor Ghogari
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to IN205MU2014 priority Critical patent/IN2014MU00205A/en
Priority to US14/600,373 priority patent/US20150202149A1/en
Publication of IN2014MU00205A publication Critical patent/IN2014MU00205A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/606Salicylic acid; Derivatives thereof having amino groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN205MU2014 2014-01-21 2014-01-21 IN2014MU00205A (enExample)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN205MU2014 IN2014MU00205A (enExample) 2014-01-21 2014-01-21
US14/600,373 US20150202149A1 (en) 2014-01-21 2015-01-20 Pharmaceutical compositions of mesalamine suppositories

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN205MU2014 IN2014MU00205A (enExample) 2014-01-21 2014-01-21

Publications (1)

Publication Number Publication Date
IN2014MU00205A true IN2014MU00205A (enExample) 2015-08-28

Family

ID=53543846

Family Applications (1)

Application Number Title Priority Date Filing Date
IN205MU2014 IN2014MU00205A (enExample) 2014-01-21 2014-01-21

Country Status (2)

Country Link
US (1) US20150202149A1 (enExample)
IN (1) IN2014MU00205A (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository

Also Published As

Publication number Publication date
US20150202149A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
IL247923B (en) 4-substituted nucleotide derivatives as HIV reverse transcriptase inhibitors
EP3960735C0 (en) QUINAZOLINE DERIVATIVES USED TO TREAT HIV
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
PH12016502586A1 (en) Lipid comprising docosapentaenoic acid
EP3174874A4 (en) BERBERINSALZE, URSODEOXYCHOLSALZE AND COMBINATIONS, METHOD FOR THE PRODUCTION AND THE APPLICATION THEREOF
EA201691582A1 (ru) Новые фармацевтические препараты
ZA201707303B (en) Compositions and methods for the treatment of immunodeficiency
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
GB201400442D0 (en) Compositions for use in the treatment of ulcerative colitis
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX370628B (es) Composiciones y metodos para tratar las espinillas.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
SG10201900598TA (en) Factor viii formulation
IN2014MU00916A (enExample)
IN2014CH00840A (enExample)
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii
PH12017501897A1 (en) 2-thiopyrimidinones
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
PH12018501166B1 (en) Concentrated gibberellin solution formulations
IN2014MU00205A (enExample)